| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YEXCR.2008.10.008 |
| P8608 | Fatcat ID | release_nhhy5c77tffezmjbgm4lalvcpi |
| P932 | PMC publication ID | 2726996 |
| P698 | PubMed publication ID | 18992239 |
| P2093 | author name string | Kathryn M Ferguson | |
| Karl R Schmitz | |||
| P2860 | cites work | Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model | Q77555291 |
| A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies | Q79382565 | ||
| Recent advances in head and neck cancer | Q81950649 | ||
| EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization | Q24296900 | ||
| Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha | Q24307630 | ||
| Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains | Q24307661 | ||
| Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface | Q24529941 | ||
| The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand | Q24536067 | ||
| ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 | ||
| Structure of the extracellular region of HER3 reveals an interdomain tether | Q27639450 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8 | Q27649857 | ||
| Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization | Q27650259 | ||
| Signal transduction by receptors with tyrosine kinase activity | Q27860624 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| A radioimmunoassay for human epidermal growth factor receptor | Q72400254 | ||
| Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors | Q72403213 | ||
| A monoclonal antibody to the human epidermal growth factor receptor | Q72695320 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product | Q28256232 | ||
| Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425 | Q28277177 | ||
| Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies | Q28282033 | ||
| Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide | Q28304050 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility | Q30481746 | ||
| A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies | Q30717070 | ||
| Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. | Q31016741 | ||
| Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display | Q31108093 | ||
| Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy | Q33837881 | ||
| EGF mutant receptor vIII as a molecular target in cancer therapy | Q33950534 | ||
| Implications of epidermal growth factor (EGF) induced egf receptor aggregation | Q34091453 | ||
| Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice | Q34169387 | ||
| Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor | Q34180911 | ||
| Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy | Q34187436 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor | Q34470390 | ||
| Extracellular domains drive homo- but not hetero-dimerization of erbB receptors | Q34488149 | ||
| A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions | Q34587922 | ||
| Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies | Q34708312 | ||
| A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors | Q35652789 | ||
| The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function | Q35729931 | ||
| A structure-based model for ligand binding and dimerization of EGF receptors | Q35730035 | ||
| Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors | Q35925840 | ||
| The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. | Q35975667 | ||
| Critical update and emerging trends in epidermal growth factor receptor targeting in cancer | Q36064490 | ||
| High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses | Q36222608 | ||
| Human antibodies from transgenic animals | Q36252986 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. | Q36366519 | ||
| Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor | Q36383082 | ||
| Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system | Q36423352 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications | Q36646936 | ||
| Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. | Q36708974 | ||
| Breast cancer: the upgraded role of HER-3 and HER-4. | Q36718744 | ||
| p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor | Q36767887 | ||
| The role of the EGFR signaling in tumor microenvironment. | Q36951215 | ||
| Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer | Q37011976 | ||
| Herceptin | Q37028997 | ||
| Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). | Q37052752 | ||
| ErbB-directed immunotherapy: antibodies in current practice and promising new agents | Q37059364 | ||
| Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer | Q37110980 | ||
| The ERBB3 receptor in cancer and cancer gene therapy | Q37135372 | ||
| Ligand-induced ErbB receptor dimerization | Q37154122 | ||
| Structure-based view of epidermal growth factor receptor regulation | Q37197992 | ||
| Effector mechanisms of therapeutic antibodies against ErbB receptors | Q37201804 | ||
| Novel human antibody therapeutics: the age of the Umabs | Q37243228 | ||
| Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody | Q37605237 | ||
| The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells | Q38353126 | ||
| ErbB4 targeting approaches for prostate cancer treatment | Q39951255 | ||
| Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies | Q39987363 | ||
| A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. | Q40448458 | ||
| Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy | Q40512625 | ||
| ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface | Q40540606 | ||
| Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor | Q40568272 | ||
| CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. | Q40579345 | ||
| Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity | Q40642471 | ||
| Neuregulin expression, function, and signaling in human ovarian cancer cells. | Q40684500 | ||
| Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors | Q41590853 | ||
| Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies | Q41894678 | ||
| Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha | Q41895175 | ||
| Ligand-induced structural transitions in ErbB receptor extracellular domains | Q42032357 | ||
| Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene | Q42817276 | ||
| Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. | Q43879745 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy | Q44389281 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. | Q45943467 | ||
| Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor | Q46051292 | ||
| Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene | Q48647863 | ||
| Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis | Q51249291 | ||
| The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen | Q52827123 | ||
| Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies | Q53436863 | ||
| Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies | Q56908849 | ||
| Binding of phorbol dibutyrate and epidermal growth factor to cultured human epidermal cells | Q67279144 | ||
| A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections | Q67557093 | ||
| Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase acti | Q70218958 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 659-670 | |
| P577 | publication date | 2008-10-22 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Experimental Cell Research | Q1524289 |
| P1476 | title | Interaction of antibodies with ErbB receptor extracellular regions | |
| P478 | volume | 315 |
| Q39552974 | A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. |
| Q36748708 | A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. |
| Q36795486 | A view on EGFR-targeted therapies from the oncogene-addiction perspective. |
| Q33893381 | Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models |
| Q30412654 | Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells |
| Q35660279 | Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization |
| Q35842099 | Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling |
| Q48140622 | Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics |
| Q39011809 | Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling |
| Q48117891 | Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding. |
| Q37250084 | Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. |
| Q52578959 | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients |
| Q39272792 | Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods |
| Q39149961 | Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. |
| Q50847753 | Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fluorescence lifetime imaging microscopy |
| Q37132708 | EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q37893414 | Emerging antibody combinations in oncology |
| Q49671739 | Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains |
| Q35031462 | Examination of HER3 targeting in cancer using monoclonal antibodies |
| Q39011393 | Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli |
| Q82513915 | In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor |
| Q55000376 | Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. |
| Q35590849 | Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping |
| Q37736496 | Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma |
| Q39242623 | Ligand binding induces a conformational change in epidermal growth factor receptor dimers. |
| Q28485296 | Molecular determinants of epidermal growth factor binding: a molecular dynamics study |
| Q38548814 | Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. |
| Q39379086 | Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. |
| Q35569418 | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets |
| Q41416393 | Phage display-derived human antibodies in clinical development and therapy |
| Q38207923 | Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients |
| Q37658764 | Potential of ErbB4 antibodies for cancer therapy. |
| Q34703343 | Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display human scFv against EGFR |
| Q35624032 | Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor |
| Q31113275 | Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells |
| Q37468539 | Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies |
| Q39645878 | Strength in numbers: effects of acceptor abundance on FRET efficiency |
| Q27678732 | Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains |
| Q26853162 | Structure-function relationships of ErbB RTKs in the plasma membrane of living cells |
| Q38015668 | Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy |
| Q38129286 | Targeting the ERBB family in cancer: couples therapy |
| Q34719632 | Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies |
| Q37633126 | Tissue-specific targeting based on markers expressed outside endothelial cells |
| Q42558684 | Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology? |
| Q48465476 | mAb806 binding to epidermal growth factor receptor: a computational study |
Search more.